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Summary table
What is known on this topic
 Limited data are available that describe idarucizumab utilisation in routine clinical 
practice.
 Post-marketing observational studies can provide insight into the use of medications 
in the real world where there is a broad patient population with various comorbidities 
and concomitant therapies.
What this paper adds
 It provides the first insight into how a NOAC reversal agent is used in the real-world 
setting, examining where idarucizumab is prescribed (across regions and within 
hospitals), the patients who receive idarucizumab, and why they received it.
 The RE-VECTO study confirmed that 5 g of idarucizumab was used appropriately in 
> 98% of dabigatran-treated patients with life-threatening bleeding or in need of 
emergency surgery.
































































 Idarucizumab use was generally consistent with the data collected in the clinical trial 
setting with minimal off-label prescribing.

































































Idarucizumab was approved for the reversal of dabigatran in 2015. We investigated whether 
post-approval usage patterns of idarucizumab in a real-world setting reflect those observed 
in the pivotal trials. No safety or efficacy data were collected in this medical record-based 
observational study. RE-VECTO, a global post-approval, international, surveillance 
programme, involved hospital pharmacies in countries where idarucizumab was licensed 
and dispensed (August 2016 to June 2018). Characteristics of sites prescribing idarucizumab 
and of eligible patients (≥ 18 years old and receiving idarucizumab regardless of prior oral 
anticoagulant use), as well as idarucizumab utilisation data, were collected and analysed 
descriptively. Sixty-one sites enrolled 359 patients. Most pharmacies (85.2%) were 
centralised, and the median idarucizumab units stocked per hospital was 2.0 (interquartile 
range, 1.0 to 3.0). Almost three-quarters of patients were elderly (74.9% aged > 70 years), 
and only four (1.1%) had received idarucizumab before. Nearly all patients were treated 
with dabigatran (97.5%). There was low usage of unapproved dabigatran dosage regimens 
(3.3%). Life-threatening or uncontrolled bleeding was the most frequent indication for 
idarucizumab (57.7%), followed by emergency surgery/urgent procedure (35.9%). Of the 
life-threatening bleeding events, the most frequent were gastrointestinal tract (44.4%) and 
intracranial (38.6%). Most patients (95.0%) were given the full dose of two vials (2 × 2.5 g) of 
idarucizumab initially, and very few (1.7%) received a second dose. Of those patients 
requiring emergency or scheduled/planned surgery/procedures, 25.5% underwent 
gastrointestinal and/or abdominal surgery/procedures. Real-world usage patterns of 
idarucizumab provide valuable insights into emergency reversal strategies. Off-label use was 
minimal. 

































































Anticoagulant reversal is central to the management of uncontrolled bleeding in 
anticoagulated patients and, where possible, in those on anticoagulants who require 
emergency surgery or other invasive procedures.1 The strategy undertaken to attempt 
reversal will vary according to the type of anticoagulant in use and availability of reversal 
agents. Non-vitamin K antagonist oral anticoagulants (NOACs), including the direct thrombin 
inhibitor dabigatran and the factor Xa antagonists (rivaroxaban, apixaban, edoxaban and 
betrixaban), are now recommended in guideline statements as the preferred agents in most 
clinical settings due to their similar efficacy and lower bleeding risk compared with vitamin K 
antagonists (VKAs).2-4 Reversal of NOACs was not possible until 2015, when idarucizumab 
became commercially available in the United States of America (USA) and European Union 
(EU) for the specific reversal of dabigatran.5,6 Andexanet alfa was approved in 2018 in the 
USA for the treatment of rivaroxaban- and apixaban-associated bleeding in patients, but is 
not yet available elsewhere, nor is it approved for use in surgical patients.7 Prior to this, 
treatment was limited to non-specific empiric approach s (e.g. administration of blood or 
blood derivatives, or waiting until anticoagulant activity had waned). Non-specific 
approaches are still used in countries that have no approved specific reversal agents, and in 
bleeding associated with oral anticoagulants (OACs) for which there are no specific reversal 
agents available.
Idarucizumab is a humanised mouse monoclonal antibody fragment that binds directly 
to dabigatran with high affinity, reversing its anticoagulant effects within minutes.8,9 In the 
phase III RE-VERSE AD (NCT02104947) trial, idarucizumab rapidly and completely reversed 
dabigatran’s anticoagulant effect in almost all patients with life-threatening or uncontrolled 
































































bleeding or those requiring emergency surgery or procedures. In addition, no safety 
concerns, specifically anaphylaxis or pro-thrombotic effects, were reported.10 Dabigatran is 
indicated to reduce the risk of stroke and systemic embolism in non-valvular atrial 
fibrillation, to treat deep venous thrombosis (DVT) and pulmonary embolism (PE), to 
prevent recurrent DVT, and PE in adults (DVT/PE) and for primary prevention of VTE in 
orthopaedic surgery.11,12 Idarucizumab (5 g initially; two 50 mL vials each containing 2.5 g 
idarucizumab constitute one complete 5 g dose [a second 5 g dose may be considered under 
specific clinical circumstances]) is indicated in adult patients when rapid reversal of 
dabigatran is required for life-threatening or uncontrolled bleeding or emergency 
surgery/urgent procedures.13,14 
In order to characterise the utilisation of idarucizumab and provide data on usage 
patterns in a real-world setting, RE-VECTO, a global drug administration surveillance 
programme, was initiated.
Methods and Analysis
Programme Design and Participants
RE-VECTO, an international, multicentre, cross-sectional surveillance programme, was a 
post-approval study commitment for the European regulatory authorities. RE-VECTO 
involved hospital pharmacies or departments in North America, the European Union, and 
the Asia-Pacific region, where idarucizumab was dispensed between August 2016 and June 
2018, depending on marketing authorisation, country regulations and requirements, and 
availability of the protocol. 
































































In countries where idarucizumab was approved, potential sites where idarucizumab 
was dispensed were identified and invited to register; after which data were collected via a 
retrospective chart review. Initially, all centres who ordered idarucizumab were sent a 
welcome pack and invited to register on the website. The response rate was low and the 
process was redefined to include only those centres that ordered and then restocked 
idarucizumab. However, this was not necessarily indicative of use of idarucizumab as 
reorders could be for multiple reasons (i.e. supplying satellite locations within the hospital 
or towards the end of the trial- replacing expired product). In total, over 2000 invitations 
were sent, and other methods were used to narrow site selection to those with known 
patients receiving the product (i.e. claims data or medical science liaison conversations). All 
centres who registered, completed required training, and finalized the required trial 
documents were activated, regardless if they had an identified patient or not.
Idarucizumab was prescribed at the discretion of the treating physician and not 
influenced by participation in the programme. Prescription of idarucizumab other than 
indicated by the label was considered as off-label use, such as an unapproved indication 
(e.g. elective surgery), an unapproved dose (e.g. 2.5 g), or treatment of a patient who did 
not receive dabigatran. Patients aged ≥ 18 years receiving idarucizumab as part of their 
clinical care were eligible, regardless of prior OAC use. Any patients participating in a 
dabigatran or idarucizumab clinical trial were excluded.
Informed consent was not required because the programme was based on 
anonymised data. The protocol was approved by an independent ethics committee where 
necessary, based on country-specific regulations.
Data Collection
































































In patients treated with idarucizumab, anonymised patient data were entered into an 
electronic data capture system via an internet portal. A pre-specified data-management 
plan and pre-specified rules generated auto-queries for missing fields, and data listing 
reviews were conducted prior to database lock. Patient demographics such as age 
categories and previous anticoagulant use (e.g., last intake of dabigatran etexilate or other 
OACs), were collected. Previous antiplatelet treatment, safety and efficacy data were not 
collected. 
Idarucizumab utilisation, including the reason for idarucizumab use (life-threatening or 
uncontrolled bleeding requiring medical intervention, or emergency surgery or other urgent 
medical procedure necessitating rapid reversal of the anticoagulant effect of dabigatran), 
was recorded. Information regarding the location of the bleeding event (gastrointestinal 
tract, intracranial, post-procedural, skin, urogenital tract, undefined location, other defined 
location) was also collected. In addition, the dosage and timing of idarucizumab 
administration (total dose administered and the time interval between administration of the 
first and second vials [the standard approved dosage is 2 × 2.5 g vials]), whether 
idarucizumab administration was discontinued prematurely, and the care setting (for 
example, emergency department, intensive care unit or operating Room) were recorded. 
The characteristics of the hospital pharmacy were collected for each participating site 
to evaluate the diversity of sites, including: country, whether the pharmacy was central or 
decentralised, the number of pharmacy units within the hospital if there is no central 
pharmacy (e.g. the emergency department, intensive care unit or operating room), 
idarucizumab stocks, storage location, distribution channels within the hospital, type of 
































































practice (academic, non-academic, private or public) and availability of electronic 
prescription records at the pharmacy. 
Statistical Analysis
The programme sample size was driven by regulatory requirements, and idarucizumab 
usage and provider participation. A minimum of 300 patients was requested by the 
European Medicines Agency. 
Data from all enrolled patients who received idarucizumab were analysed using 
descriptive statistics (generated using SAS® version 9.2 or higher [SAS Institute, Cary, NC, 
USA]). Categorical variables were summarised as numbers and proportions. Continuous 
variables are reported as mean (standard deviation [SD]) or median (interquartile ranges 
[IQR]). Subgroups analysed included; region, indication for use of idarucizumab, age, prior 
administration of idarucizumab, department where idarucizumab was administered, 
bleeding event location and type, and whether the bleeding was life-threatening. Missing 
data were not imputed.
Results
Characteristics of Sites Prescribing Idarucizumab
Of the 132 registered hospitals, 61 sites enrolled 359 patients (eight sites in the Asia Pacific 
region, 42 sites in the EU, and 29 sites in North America). Just over half (52.5%]) were non-
academic institutions, and the majority were public hospitals (67.2%]) (Table 1).
Most pharmacies (85.2%) were centralised. In sites with decentralised pharmacies, the 
median number of pharmacy units per hospital was 8.0 (IQR 2.0–9.0) (Table 1). The majority 
































































of hospitals (78.7%) had electronic prescription and electronic medical records available, 
and stored idarucizumab in the primary pharmacy (67.2%). Other storage locations including 
satellite pharmacies, Emergency Department, Intensive Care Unit or Operating Room, and 
other specialist departments (Cardiology and Neurology). The median total idarucizumab 
units (one unit = 2 × 2.5 g vials) stocked per hospital pharmacy in all storage locations was 
2.0 (IQR 1.0 to 3.0). 
Characteristics of Patients Treated with Idarucizumab
Of the 359 enrolled patients, most were either in the EU (152/359 [42.3%]) or North 
America (157/359 [43.7%], of whom 140 were enrolled in the USA) (Table 2). The majority 
of patients were treated in hospitals that were academic (208/359 [57.9%]) and public 
(238/359 [66.3%]).
Four (1.1%) patients had received idarucizumab previously, and this information was 
missing for 50 (13.9%) patients. Most patients were aged > 70 years (74.9%) and 85.0% had 
not received idarucizumab before (98.7% if excluding the 50 patients with unknown prior 
use). The dose and last intake of previous anticoagulant medications (dabigatran and/or 
other) is shown in Table 3. All patients had received an anticoagulant before recruitment. 
Dabigatran was the last anticoagulant used by most patients (97.5%), and of these, only two 
(0.6%) patients were taking dabigatran and another oral or parenteral anticoagulant (both 
had life-threatening or uncontrolled bleeding). Of the nine patients without dabigatran 
documented as their last anticoagulant medication, four had received rivaroxaban or an 
unknown anticoagulant, and one had received apixaban. Dabigatran dosage regimens (eight 
types were recorded) were known for 332 patients, with the most frequent being 150 mg 
twice daily (bid; 52.4%) and 110 mg bid (35.8%). Of those patients receiving dabigatran 110 
































































mg bid or 150 mg bid, 89.9% and 60.3% were aged > 70 years. The dose of dabigatran was 
not recorded for 18 (5.0%) patients.
Utilisation of Idarucizumab
Most patients (341/359 [95.0%]) received the full dose (2 × 2.5 g) of idarucizumab, with the 
mean (SD) time between vials being 15.3 (8.6) minutes (Table 4); time between two vials 
was missing for 123/341 (36.1%) patients. Of the 18 patients who were documented as not 
receiving the full dose of idarucizumab initially, 12 received one vial (2.5 g) and the dose was 
unknown for the other six. A second treatment with 5 g of idarucizumab, based on clinical 
signs in combination with coagulation tests, was administered to six patients (1.7%), either 
in the Emergency Department (n = 2) or Intensive Care Unit (n = 4). The mean (SD) time 
between vials for the second treatment was 14.0 (7.1) minutes, with the time between two 
vials missing in 2/6 (33.0%) patients. Of the six patients requiring a second full dose of 
idarucizumab, five given idarucizumab for initial life-threatening or uncontrolled bleeding 
required the second treatment for additional urgent intervention (n = 1) or for re-
bleeding/prolonged coagulation test (n = 4); one patient given idarucizumab initially for 
emergency surgery/urgent medical procedures required the second treatment for 
prolonged re-bleeding/prolonged coagulation test. No adverse events were reported in any 
patient.
Idarucizumab was primarily administered in the Emergency Department (209/359 
[58.2%]). Bleeding was the most frequent indication for the administration of idarucizumab 
(207/359 [57.7%] patients), followed by emergency surgery/urgent procedure (129/359 
[35.9%] patients). This pattern was consistent in most departments, except for the surgical 
department. 
































































The most frequent bleeding events were gastrointestinal (GI) tract (92/207 [44.4%] of 
patients) and intracranial (80/207 [38.6%]) (Fig. 1). Most patients with GI bleeding (88/92 
[95.7%]) received the full dose (2 × 2.5 g) of idarucizumab, with the mean (SD) time between 
vials being 15.2 (9.8) minutes. Similarly, the majority of patients with intracranial bleeding 
(76/80 [95.0%]) received the full dose of idarucizumab, with the mean (SD) time between 
vials being 16.3 (7.1) minutes. Of the 194/207 (93.7%) patients who received the full dose (2 
× 2.5 g) of idarucizumab for a bleeding event, the time between two vials was not available 
for 68/194 (35.1%) patients. For those patients who received the full dose (2 × 2.5 g) of 
idarucizumab for GI or intracranial bleeding events, the time between two vials was not 
available for 28/88 (31.8%) and 25/76 (32.9%) patients, respectively. Four patients (1.1%) 
were reported to have prematurely discontinued idarucizumab, with none due to adverse 
events. 
Of the 141 (39.3%) patients who were administered idarucizumab for emergency or 
for scheduled or planned surgery/procedure (Fig. 2), GI and/or abdominal surgery or 
procedures were most frequently performed (in 36 [25.5%] of patients), followed by 
orthopaedic procedures (in 31 [22.0%] patients), thoracic surgery including cardiac surgery 
(23 [16.3%] patients), and vascular operations (in 20 [14.2%] patients). Of the 23 patients 
who received idarucizumab for thoracic surgery including cardiac surgery, six patients 
underwent cardiac catheterization, three patients had a cardiac pacemaker insertion or 
removal, one patient had a central venous catheterization, and five patients had a 
pericardial excision and pericardial drainage. No intra-procedural bleeds were reported. The 
study also included patients who required rapid reversal of the anticoagulant effect of 
dabigatran prior to thrombolysis (n = 12) and thrombectomy (n = 2). On average, data were 
missing for 6.4% of patients with regard to the type of surgery/procedure; 8/129 (6.2%) 
































































patients who underwent emergency surgery or other urgent medical procedures, and 1/12 
(8.3%) patients who underwent scheduled or planned surgery/procedures. 
Discussion
The RE-VECTO post-approval surveillance study has shown that sites prescribing 
idarucizumab were mainly non-academic institutions and public hospitals, with 
approximately two doses of idarucizumab stored on-site. Most of the patients were 
European or North American. More than half of the registered hospitals either registered 
proactively prior to identification of a patient treated with idarucizumab or  had historical 
cases of patients treated with idarucizumab but did not enter patients into the registry. Of 
those sites that entered patient data, as expected, dabigatran was the anticoagulant used 
by most patients. Nearly all patients received the full dose (2 × 2.5 g) of idarucizumab, with 
only one full dose required in almost all patients. There was minimal off-label dosing (e.g., 
use of 2.5 g in 12 patients), and administration of idarucizumab to seven patients using FXa 
inhibitors (without dabigatran) was reported. . As expected, idarucizumab was most 
frequently given in the Emergency Department, and bleeding (the most common locations 
being GI tract and intracranial) was the most frequent reason for administering 
idarucizumab.
The findings from RE-VECTO describing idarucizumab uptake, dabigatran prescribing 
patterns and patient characteristics in the real-world setting add to the idarucizumab clinical 
trial data and few case collections available to date.10,15-22 While the patients in RE-VECTO 
were less well characterized due to the limitations of data collection, outcomes were largely 
consistent with those observed in the clinical trial setting with regard to indications, rates of 
bleeding and emergent surgery events. In addition, RE-VECTO demonstrates that the real-
































































world usage of idarucizumab was mostly as recommended in the label. Moreover, the 
reversal of dabigatran in RE-VECTO rarely required a second round of idarucizumab dosing 
(< 2% of patients), supporting the findings from the RE-VERSE-AD study in which a second 
round of dosing was required in 1.6% patients.10 In addition, the reversal of dabigatran in 
the real-world setting involved a mainly elderly population treated with several different 
dabigatran dosage regimens. In RE-VERSE-AD, the median age was 78 (range, 21–96) years, 
and > 97% of patients received one of three approved dosage regimens of dabigatran 
(150/110/75 mg bid). 
Aside from idarucizumab, one other reversal agent, andexanet alfa, is available 
commercially in the USA for the reversal of rivaroxaban- and apixaban-related bleeding only, 
following positive results from clinical trials.23,24 Another potential FXa inhibitor reversal 
agent, ciraparantag, has yet to begin phase II or III evaluation in patient settings; phase II 
data in healthy volunteers administered rivaroxaban (NCT03172910) or apixaban 
(NCT03288454) are expected in 2019. 
The RE-VECTO surveillance programme was designed to collect data on drug use in a 
simple and effective way, although the voluntary registration design and/or resource 
limitations may have reduced participation and resulted in some incomplete datasets. Some 
recruited sites known to be prescribing idarucizumab did not enter patient data in the 
registry during the specified time period  for data collection, and were not actively surveyed. 
Data listing reviews conducted prior to database lock did not involve an independent data 
review committee, and on-site source data verification was not conducted. Administration 
of idarucizumab is rare, and without patient data being entered into the registry, we are 
unable to ascertain whether these sites were re-stocking idarucizumab, supplying satellite 
































































locations within the hospital, replacing expired idarucizumab, or administering idarucizumab 
to patients. Nevertheless, drug surveillance programmes are one source of real-world 
data,25 that are particularly useful for identifying improper use. By identifying potential risks, 
action can be taken to help minimise the risk of adverse drug reactions resulting from 
medication errors. This study assessed idarucizumab utilization in a pre-defined sample of 
prescriptions in the clinical practice setting, based on medical and pharmacy record review. 
This approach was in line with post-marketing surveillance requested by the European 
Medicines Agency. 
Conclusion
Real-world information from the RE-VECTO surveillance programme adds to the data 
obtained from idarucizumab clinical trials and provides valuable insights into the current 
strategies employed to reverse the anticoagulation effects of dabigatran in emergency 
situations. Usage patterns of idarucizumab were aligned with idarucizumab prescribing 
information, with minimal off-label use. 
Acknowledgements
Medical writing assistance, supported financially by Boehringer Ingelheim Pharma GmbH & 
Co. KG, was provided by PAREXEL during the preparation of this article.
Authors’ contributions
All authors were involved with designing the surveillance programme, provided critical 
review of the article and approved the final version for publication. 
Funding 
































































The RE-VECTO surveillance programme was funded by Boehringer Ingelheim Pharma GmbH 
& Co. KG.
Disclosure of interests
John Fanikos has consulted for Boehringer Ingelheim, Genentech, and Portola.
Debra Murwin, Fredrik Gruenenfelder, Paul A Reilly and Igor Tartakovsky are employees of 
Boehringer Ingelheim. 
L Riou França was an employee of Boehringer Ingelheim at the time of manuscript writing 
and is now employed by Sanofi-Aventis.
Deirdre A Lane has received investigator-initiated educational grants from Bristol-Myers 
Squibb and Boehringer Ingelheim; has been a speaker for Boehringer Ingelheim, Bayer, and 
Bristol-Myers Squibb/Pfizer; and has consulted for Bristol-Myers Squibb, Bayer, Boehringer 
Ingelheim, and Daiichi-Sankyo.
Pawel Kermer served as a speaker/has consulted for Boehringer Ingelheim, Bayer, 
BMS/Pfizer and Portola.
Frederik Von Wowern served as a speaker/has consulted for Boehringer Ingelheim, Bayer, 
BMS/Pfizer, Takeda and Leo Pharma.
Ken Butcher has served on advisory boards, received investigator-initiated research grants 
and served as a speaker for Boehringer Ingelheim, Bayer and BMS/Pfizer.

































































































































1 Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current 
developments. Thromb Haemost 2015;113:931-942 
2 Das A, Liu D. Novel antidotes for target specific oral anticoagulants. Exp Hematol 
Oncol 2015;4:25 
3 Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of 
atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-
2962 
4 Macle L, Cairns J, Leblanc K, et al. 2016 Focused update of the Canadian 
Cardiovascular Society guidelines for the management of atrial fibrillation. Can J 
Cardiol 2016;32:1170-1185 
5 European Medicines Agency. 2015. Idarucizumab summary of product 
characteristics. https://www.ema.europa.eu/documents/product-
information/praxbind-epar-product-information_en.pdf. Accessed October 10, 2018.
6 US Food and Drug Administration. 2015. Idarucizumab prescribing information. 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf. 
Accessed October 10, 2018.
7 US Food and Drug Administration. 2018. Andexanet alfa prescribing information. 
https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProd
ucts/ApprovedProducts/UCM606687.pdf. Accessed October 10, 2018.
8 Eikelboom JW, Quinlan DJ, van Ryn J, et al. Idarucizumab: the antidote for reversal of 
dabigatran. Circulation 2015;132:2412-2422 
9 Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional 
and structural characterization. Blood 2013;121:3554-3562 
10 Pollack CV, Jr., Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full 
cohort analysis. N Engl J Med 2017;377:431-441 
11 European Medicines Agency. Dabigatran etexilate. Summary of Product 
Chacrateristics. https://www.ema.europa.eu/documents/product-
information/pradaxa-epar-product-information_en.pdf. Accessed October 10, 2018.
12 US Food and Drug Administration. Dabigatran etexilate prescribing information. 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022512s035lbl.pdf. 
Accessed October 10, 2018.
13 European Medicines Agency. Idarucizumab. Summary of Product Characteristics. 
https://www.ema.europa.eu/documents/product-information/praxbind-epar-
product-information_en.pdf. Accessed October 10, 2018.
14 US Food and Drug Administration. Idarucizumab prescribing information. 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf. 
Accessed October 10, 2018.
15 Pollack CV, Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N 
Engl J Med 2015;373:511-520 
16 Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of 
idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy 
male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. 
Lancet 2015;386:680-690 
































































17 van Ryn J, Yasaka M, Ikushima I, et al. Idarucizumab, a specific reversal agent for 
dabigatran: immediate, complete and sustained reversal of dabigatran-induced 
anticoagulation in Japanese healthy male volunteers. Blood 2016;128(suppl 22):2627 
18 Glund S, Stangier J, van Ryn J, et al. Effect of age and renal function on idarucizumab 
pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant 
activity in a randomized, double-blind, crossover phase Ib study. Clin Pharmacokinet 
2017;56:41-54 
19 Glund S, Stangier J, Schmohl M, et al. Idarucizumab, a specific antidote for 
dabigatran: immediate, complete and sustained reversal of dabigatran induced 
anticoagulation in elderly and renally impaired subjects. Blood 2014;124(suppl 
21):344 
20 Fang CW, Tsai YT, Chou PC, et al. Intravenous thrombolysis in acute ischemic stroke 
after idarucizumab reversal of dabigatran effect: Analysis of the cases from Taiwan. J 
Stroke Cerebrovasc Dis 2019;28:815-820 
21 Kermer P, Eschenfelder CC, Diener HC, et al. Antagonizing dabigatran by 
idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A 
national case collection. Int J Stroke 2017;12:383-391 
22 van der Wall SJ, van Rein N, van den Bemt B, et al. Performance of idarucizumab as 
antidote of dabigatran in daily clinical practice. Europace 2018 
23 Connolly SJ, Milling TJ, Jr., Eikelboom JW, et al. Andexanet alfa for acute major 
bleeding associated with factor Xa inhibitors. N Engl J Med 2016;375:1131-1141 
24 Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa 
inhibitor activity. N Engl J Med 2015;373:2413-2424 
25 Martin K, Begaud B, Latry P, et al. Differences between clinical trials and 
postmarketing use. Br J Clin Pharmacol 2004;57:86-92 

































































Fig. 1 Location of bleedinga events (N = 207) leading to idarucizumab use, and idarucizumab 
use by bleeding location. 
aLife-threatening or uncontrolled bleeding requiring medical intervention.
b Calculated only for those patients administered total dose of 5 g (2 vials), and defined as 
the end time of second vial minus the start time of the first vial. If the start or end time of 
dosing was unknown, the estimated time of total infusion was used; if this estimate was not 
known, then time was set to missing.
c Missing data for 28 patients with gastrointestinal tract bleeding, 25 with intracranial 
bleeding, 3 with skin bleeding, 3 with urogenital tract bleeding, 1 with intramuscular 
bleeding, 2 with retroperitoneal bleeding, and 6 with other bleeding locations.
































































Abbreviations: GI, gastrointestinal; NE, not evaluable; SD, standard deviation.
































































Fig. 2 Type of surgery or procedure by indication for idarucizumab use. 
a Missing data for 8 patients undergoing emergency surgery or other urgent medical 
procedures.
b Missing data for 1 patient undergoing scheduled or planned surgery/procedures.

































































Table 1 Hospitals treating patients with idarucizumab by region



















































































































































































Availability of electronic prescription records at 

































Total number of idarucizumab units (2 × 2.5 g) 
stocked per hospital pharmacy in all storage 
locationsc, n (%)
8 24 28 60
































































Median (IQR) 2.0 (1.0, 3.0) 2.0 (2.0, 3.5) 2.0 (1.0, 2.0) 2.0 (1.0, 3.0)





















a Type 1: academic sector type; Type 2: practice hospital type.
b Only available when type of pharmacy is decentralised pharmacy.
c Data for 1 hospital pharmacy missing for North America.
d Multiple answers possible. 
Abbreviations: IQR, interquartile range.
































































Table 2 Characteristics of patients treated with idarucizumab by region



















































































































































































Other 0 ( 0.0) 0 (0.0) 5 ( 3.2) 5 (1.4)
















a Type 1: academic sector type; Type 2: practice hospital type.
































































Table 3 Last anticoagulant medication taken prior to recruitment, according to the reason for idarucizumab administration





















































































































































a Includes two patients who received ≥ 1 dose dabigatran plus other anticoagulant.
b Includes two patients who were receiving another known anticoagulant medication.











































































































Table 4 Idarucizumab utilisation according to the reason for idarucizumab administration





















































































Idarucizumab total dose, n (%)
2.5 g (1 vial)































































































































































































a Life-threatening or uncontrolled bleeding requiring urgent medical intervention.
b Emergency surgery or other urgent medical procedure necessitating rapid reversal of dabigatran prior to surgery or procedure (emergency 
defined as within the next 8 hours).
c Calculated only for those patients administered total dose of 5 g (2 vials), and defined as the end time of second vial minus the start time of 
the first vial. If the start or end time of dosing was unknown, the estimated time of total infusion was used; if this estimate was not known, 
then time was set to missing.
d Missing data for 68 patients in the Emergency setting, 40 in the Operating setting, 5 in the intensive care setting, and 10 in the Other setting.
e Among patients who had second round of dosing with 5 g of idarucizumab.
f Missing data for 1 patient in the Emergency and ICU settings.
Abbreviations: SD, standard deviation.
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Summary table
What is known on this topic
 Limited data are available that describe idarucizumab utilisation in routine clinical 
practice.
 Post-marketing observational studies can provide insight into the use of medications 
in the real world where there is a broad patient population with various comorbidities 
and concomitant therapies.
What this paper adds
 It provides the first insight into how a NOAC reversal agent is used in the real-world 
setting, examining where idarucizumab is prescribed (across regions and within 
hospitals), the patients who receive idarucizumab, and why they received it.
 The RE-VECTO study confirmed that 5 g of idarucizumab was used appropriately in 
> 98% of dabigatran-treated patients with life-threatening bleeding or in need of 
emergency surgery.
































































 Idarucizumab use was generally consistent with the data collected in the clinical trial 
setting with minimal off-label prescribing.

































































Idarucizumab was approved for the reversal of dabigatran in 2015. We investigated whether 
post-approval usage patterns of idarucizumab in a real-world setting reflect those observed 
in the pivotal trials. No safety or efficacy data were collected in this medical record-based 
observational study. RE-VECTO, a global post-approval, international, surveillance 
programme, involved hospital pharmacies in countries where idarucizumab was licensed 
and dispensed (August 2016 to June 2018). Characteristics of sites prescribing idarucizumab 
and of eligible patients (≥ 18 years old and receiving idarucizumab regardless of prior oral 
anticoagulant use), as well as idarucizumab utilisation data, were collected and analysed 
descriptively. Sixty-one sites enrolled 359 patients. Most pharmacies (85.2%) were 
centralised, and the median idarucizumab units stocked per hospital was 2.0 (interquartile 
range, 1.0 to 3.0). Almost three-quarters of patients were elderly (74.9% aged > 70 years), 
and only four (1.1%) had received idarucizumab before. Nearly all patients were treated 
with dabigatran (97.5%). There was  a low usagefrequency of unapproved dabigatran 
dosage regimens (3.3%). Life-threatening or uncontrolled bleeding was the most frequent 
indication for idarucizumab (57.7%), followed by emergency surgery/urgent procedure 
(35.9%). Of the life-threatening bleeding events, the most frequent were gastrointestinal 
tract (44.4%) and intracranial (38.6%). Most patients (95.0%) were given the full dose of two 
vials (2 × 2.5 g) of idarucizumab initially, and very few (1.7%) received a second dose. Of 
those patients requiring emergency or scheduled/planned surgery/procedures, 25.5% 
underwent gastrointestinal and/or abdominal surgery/procedures. Real-world usage 
patterns of idarucizumab provide valuable insights into emergency reversal strategies. Off-
label use was minimal. provides valuable insights into the current strategies employed to 
































































reverse the anticoagulation effects of dabigatran in emergency situationsclosely matched 
data from the clinical trial setting, with minimal off-label use. 

































































Anticoagulant reversal is central to the management of uncontrolled bleeding in 
anticoagulated patients and, where possible, in those on anticoagulants who require 
emergency surgery or other invasive procedures.1 The strategy undertaken to attempt 
reversal will vary according to the type of anticoagulant in use and availability of reversal 
agents. Non-vitamin K antagonist oral anticoagulants (NOACs), including the direct thrombin 
inhibitor dabigatran and the factor Xa antagonists (rivaroxaban, apixaban, edoxaban and 
betrixaban), are now recommended in guideline statements as the preferred agents in most 
clinical settings due to their similar efficacy and lower bleeding risk compared with vitamin K 
antagonists (VKAs).2-4 Reversal of NOACs was not possible until 2015, when idarucizumab 
became commercially available in the United States of America (USA) and European Union 
(EU) for the specific reversal of dabigatran.5,6 Andexanet alfa was approved in 2018 in the 
USA for the treatment of rivaroxaban- and apixaban-associated bleeding in patients, but is 
not yet available elsewhere, nor is it approved for use in surgical patients.7 Prior to this, 
treatment was limited to non-specific empiric approach s (e.g. administration of blood or 
blood derivatives, or waiting until anticoagulant activity had waned). Non-specific 
approaches are still used in countries that have no approved specific reversal agents, and in 
bleeding associated with oral anticoagulants (OACs) for which there are no specific reversal 
agents available.
Idarucizumab is a humanised mouse monoclonal antibody fragment that binds directly 
to dabigatran with high affinity, reversing its anticoagulant effects within minutes.8,9 In the 
phase III RE-VERSE AD (NCT02104947) trial, idarucizumab rapidly and completely reversed 
dabigatran’s anticoagulant effect in almost all patients with life-threatening or uncontrolled 
































































bleeding or those requiring emergency surgery or procedures. In addition, no safety 
concerns, specifically anaphylaxis or pro-thrombotic effects, were reported.10 Dabigatran is 
indicated to reduce the risk of stroke and systemic embolism in non-valvular atrial 
fibrillation, to treat deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients 
treated with a parenteral anticoagulant for 5–-10 days, to prevent recurrent DVT, and PE in 
adults (DVT/PE) and for primary prevention of VTE in orthopaedic surgeryreduce the risk of 
recurrence of DVT and PE in previously treated patients, and for the prophylaxis of DVT and 
PE in patients who have undergone hip or knee replacement surgery.11,12 Idarucizumab (5 g 
initially;  two 50 mL vials each containing 2.5 g idarucizumab constitute one complete 5 g 
dose [a second 5 g dose may be considered under specific clinical circumstances]) is 
indicated in adult patients when rapid reversal of dabigatran is required for life-threatening 
or uncontrolled bleeding or emergency surgery/urgent procedures.13,14 
In order to characterise the utilisation of idarucizumab and provide data on usage 
patterns in a real-world setting, RE-VECTO, a global drug administration surveillance 
programme, was initiated.
Methods and Analysis
Programme Design and Participants
RE-VECTO, an international, multicentre, cross-sectional surveillance programme, was a 
post-approval study commitment for the European regulatory authorities. RE-VECTO 
involved hospital pharmacies or departments in North America, the European Union, and 
the Asia-Pacific region, where idarucizumab was dispensed between August 2016 and June 
































































2018, depending on marketing authorisation, country regulations and requirements, and 
availability of the protocol. 
In countries where idarucizumab was approved, potential sites where idarucizumab 
was dispensed were identified and invited to register; after which data were collected via a 
retrospective chart review. Initially, all centres who ordered idarucizumab were sent a 
welcome packet and invited to register on the website. The rResponse rate was low and the 
process was redefined to include only those centres that ordered and then restocked 
idarucizumabproduct. However, this was not necessarily indicative of use of idarucizumab 
as reorders could be for multiple reasons (i.e. supplying satellite locations within the 
hospital or towards the end of the trial- replacing expired product). In total, over 2000 
invitations were sent, and other methods were used to narrow site selection to those with 
known patients receiving the product (i.e. claims data or medical science liaisonMSL 
conversations). All centres who registered, completed required training, and finalized the 
required trial documents were activated, regardless if they had an identified patient or not.
Idarucizumab was prescribed at the discretion of the treating physician and not 
influenced by participation in the programme.  Prescription of idarucizumab other than 
indicated by the label was considered as off-label use, such as an unapproved indication 
(e.g. elective surgery), an unapproved dose (e.g. 2.5 g), or treatment of a patient who did 
not receive dabigatran. Patients aged ≥ 18 years receiving idarucizumab as part of their 
clinical care were eligible, regardless of prior OAC use. Any patients participating in a 
dabigatran or idarucizumab clinical trial were excluded.
































































Informed consent was not required because the programme was based on 
anonymised data. The protocol was approved by an independent ethics committee where 
necessary, based on country-specific regulations.
Data Collection
In patients treated with idarucizumab, anonymised patient data were entered into an 
electronic data capture system via an internet portal. A pre-specified data-management 
plan and pre-specified rules generated auto-queries for missing fields, and data listing 
reviews were conducted prior to database lock. Patient demographics such as age 
categories and previous anticoagulant use (e.g., last intake of dabigatran etexilate or other 
OACs), were collected. Previous antiplatelet treatment, safety and efficacy data were not 
collected. 
Idarucizumab utilisation, including the reason for idarucizumab use (life-threatening or 
uncontrolled bleeding requiring medical intervention, or emergency surgery or other urgent 
medical procedure necessitating rapid reversal of the anticoagulant effect of dabigatran), 
was recorded. Information regarding the location of the bleeding event (gastrointestinal 
tract, intracranial, post-procedural, skin, urogenital tract, undefined location, other defined 
location) was also collected. In addition, the dosage and timing of idarucizumab 
administration (total dose administered and the time interval between administration of the 
first and second vials [the standard approved dosage is 2 ×x 2.5 g vials]), whether 
idarucizumab administration was discontinued prematurely, and the care setting (for 
example, emergency department, intensive care unit or operating Room) were recorded. 
The characteristics of the hospital pharmacy were collected for each participating site 
to evaluate the diversity of sites, including: country, whether the pharmacy was central or 
































































decentralised, the number of pharmacy units within the hospital if there is no central 
pharmacy (e.g. the emergency department, intensive care unit or operating room), 
idarucizumab stocks, storage location, distribution channels within the hospital, type of 
practice (academic, non-academic, private or public) and availability of electronic 
prescription records at the pharmacy. 
Statistical Analysis
The programme sample size was driven by regulatory requirements, and idarucizumab 
usage and provider participation. A minimum of 300 patients was requested by the 
European Medicines Agency. 
Data from all enrolled patients who received idarucizumab were analysed using 
descriptive statistics (generated using SAS® version 9.2 or higher [SAS Institute, Cary, NC, 
USA]). Categorical variables were summarised as numbers and proportions. Continuous 
variables are reported as mean (standard deviation [SD]) or median (interquartile ranges 
[IQR]). Subgroups analysed included; region, indication for use of idarucizumab, age, prior 
administration of idarucizumab, department where idarucizumab was administered, 
bleeding event location and type, and whether the bleeding was life-threatening. Missing 
data were not imputed.
Results
Characteristics of Sites Prescribing Idarucizumab
































































Of the 132 registered hospitals, 61 sites enrolled 359 patients (eight sites in the Asia Pacific 
region, 42 sites in the EU, and 29 sites in North America). Just over half (52.5%]) were non-
academic institutions, and the majority were public hospitals (67.2%]) (Table 1).
Most pharmacies (85.2%) were centralised. In sites with decentralised pharmacies, the 
median number of pharmacy units per hospital was 8.0 (IQR 2.0– to 9.0) (Table 1). The 
majority of hospitals (78.7%) had electronic prescription and electronic medical records 
available, and stored idarucizumab in the primary pharmacy (67.2%). Other storage 
locations including satellite pharmacies, Emergency Department, Intensive Care Unit or 
Operating Room, and other specialist departments (Cardiology and Neurology). The median 
total idarucizumab units (one unit = 2 ×x 2.5 g vials) stocked per hospital pharmacy in all 
storage locations was 2.0 (IQR 1.0 to 3.0). 
Characteristics of Patients Treated with Idarucizumab
Of the 359 enrolled patients, most were either in the EU (152/359 [42.3%]) or North 
America (157/359 [43.7%], of whom 140 were enrolled in the USA) (Table 2). The majority 
of patients were treated in hospitals that were academic (208/359 [57.9%]) and public 
(238/359 [66.3%]).
Four (1.1%) patients had received idarucizumab previously, and this information was 
missing for 50 (13.9%) patients. Most patients were aged > 70 years (74.9%) and 85.0% had 
not received idarucizumab before (98.7% if excluding the 50 patients with unknown prior 
use). Four (1.1%) patients had received idarucizumab previously, and this information was 
missing for 50 (13.9%) patients. The dose and last intake of previous anticoagulant 
medications (dabigatran and/or other) is shown in Table 3. All patients had received an 
anticoagulant before recruitment. Dabigatran was the last anticoagulant used by most 
































































patients (97.5%), and of these, only two (0.6%) patients were taking dabigatran and another 
oral or parenteral anticoagulant (both had life-threatening or uncontrolled bleeding). Of the 
nine patients without dabigatran documented as their last anticoagulant medication, four 
had received rivaroxaban or an unknown anticoagulant, and one had received apixaban. 
Dabigatran dosage regimens (eight types were recorded) were known for 332 patients, with 
the most frequent being 150 mg twice daily (bid; 52.4%) and 110 mg bid (35.8%). Of those 
patients receiving dabigatran 110 mg bid or 150 mg bid, 89.9% and 60.3% were aged > 
70 years. The dose of dabigatran was not recorded for 18 (5.0%) patients.
Utilisation of Idarucizumab
Most patients (341/359 [95.0%]) received the full dose (2 × 2.5 g) of idarucizumab, with the 
mean (SD) time between vials being 15.3 (8.6) minutes (Table 4); time between two vials 
was missing for 123/341 (36.1%) patients. Of the 18 patients who were documented as not 
receiving the full dose of idarucizumab initially, 12 received one vial (2.5 g) and the dose was 
unknown for the other six. A second treatment with 5 g of idarucizumab, based on clinical 
signs in combination with coagulation tests, was administered to six patients (1.7%), either 
in the Emergency Department (n = 2) or Intensive Care Unit (n = 4). The mean (SD) time 
between vials for the second treatment was 14.0 (7.1) minutes, with the time between two 
vials missing in 2/6 (33.0%) patients. Of these six patients requiring a second full dose of 
idarucizumab, five given idarucizumab for initial life-threatening or uncontrolled bleeding 
required the second treatment for additional urgent intervention (n = 1) or for re-
bleeding/prolonged coagulation test (n = 4); one patient given idarucizumab initially for 
emergency surgery/urgent medical procedures required the second treatment for 
































































prolonged re-bleeding/prolonged coagulation test. No adverse events were reported in any 
patient.
Idarucizumab was primarily administered in the Emergency Department (209/359 
[58.2%]). Bleeding was the most frequent indication for the administration of idarucizumab 
(207/359 [57.7%] patients), followed by emergency surgery/urgent procedure (129/359 
[35.9%] patients). This pattern was consistent in most departments, except for the surgical 
department. 
The most frequent bleeding events were gastrointestinal (GI) tract (92/207 [44.4%] of 
patients) and intracranial (80/207 [38.6%]) (Fig. 1). Most patients with GI bleeding (88/92 
[95.7%]) received the full dose (2 × 2.5 g) of idarucizumab, with the mean (SD) time between 
vials being 15.2 (9.8) minutes. Similarly, the majority of patients with intracranial bleeding 
(76/80 [95.0%]) received the full dose of idarucizumab, with the mean (SD) time between 
vials being 16.3 (7.1) minutes. Of the 194/207 (93.7%) patients who received the full dose (2 
× 2.5 g) of idarucizumab for a bleeding event, the time between two vials was not available 
for 68/194 (35.1%) patients. For those patients who received the full dose (2 × 2.5 g) of 
idarucizumab for GI or intracranial bleeding events, the time between two vials was not 
available for 28/88 (31.8%) and 25/76 (32.9%) patients, respectively. Four patients (1.1%) 
were reported to have prematurely discontinued idarucizumab, with none due to adverse 
events. 
Of the 141 (39.3%) patients who were administered idarucizumab for emergency or 
for scheduled or planned surgery/procedure (Fig. 2), GI and/or abdominal surgery or 
procedures were most frequently performed (in 36 [25.5%] of patients), followed by 
orthopaedic procedures (in 31 [22.0%] patients), thoracic surgery including cardiac surgery 
































































(23 [16.3%] patients), and vascular operations (in 20 [14.2%] patients). Of the 23 patients 
who received idaricizumabidarucizumab for thoracic surgery including cardiac surgery, six 
patients underwent cardiac catheterization, three patients had a cardiac pacemaker 
insertion or removal, one patient had a central venous catheterization, and five patients had 
a pericardial excision and pericardial drainage. No intra-procedural bleeds were reported. 
The study also included patients who required rapid reversal of the anticoagulant effect of 
dabigatran prior to thrombolysis (n = 12) and thromboectomy (n = 2). On average, data 
were missing for 6.4% of patients were missing data with regard toing the type of 
surgery/procedure; 8/129 (6.2%) patients who underwent emergency surgery or other 
urgent medical procedures, and 1/12 (8.3%) patients who underwent scheduled or planned 
surgery/procedures. 
Discussion
The RE-VECTO post-approval surveillance study has shown that sites prescribing 
idarucizumab were mainly non-academic institutions and public hospitals, with 
approximately two doses of idarucizumab stored on-site. Most of the patients were 
European or North American. More than half of the registered hospitals either registered 
proactively prior to identification of a patient treated with idarucizumab or who had 
historical cases of patients treated with idarucizumab and actively prescribing idarucizumab 
but did not enter patients into the registry. , perhaps due to organisational reasons. AOf 
those sites that entered patient data, as expected, dabigatran was the anticoagulant used 
by most patients. Nearly all patients received the full dose (2 ×x 2.5 g) of idarucizumab, 
Owith only one full dose was required in almost all patients. with There was minimal off-
label use dosing (e.g., use of 2.5 g in 12 patients), and administration of idarucizumab to 
































































seven patients usinge of anti-FXa inhibitors (without dabigatran) was reported. for seven 
patients. Only one full dose was required in almost all patients. As expected, idarucizumab 
was most frequently given in the Emergency Department, and bleeding (the most common 
locations being GI tract and intracranial) was the most frequent reason for administering 
idarucizumab.
The findings from RE-VECTO describing idarucizumab uptake, dabigatran prescribing 
patterns and patient characteristics in the real-world setting add to the idarucizumab clinical 
trial data and few case collections available to date.10,15-22 While the patients in RE-VECTO 
were less well characterized due to the limitations of data collection, outcomes were largely 
consistent with those observed in the clinical trial setting with regard to indications, rates of 
bleeding and emergent surgery events. In addition, RE-VECTO indicatesdemonstrates that 
the real-world usage of idarucizumab was mostly as recommended in the label. Moreover, 
the reversal of dabigatran in RE-VECTO rarely required a second round of idarucizumab 
dosing (< 2% of patients), supporting the findings from the RE-VERSE-AD study in which a 
second round of dosing was required in 1.6% patients.10 In addition, the reversal of 
dabigatran in the real-world setting involved a mainly elderly population treated with 
several different dabigatran dosage regimens. In RE-VERSE-AD, the median age was 78 
(range, 21–96) years, and > 97% of patients received one of three approved dosage 
regimens of dabigatran (150/110/75 mg bid). 
Aside from idarucizumab, one other reversal agent, andexanet alfa, is available 
commercially in the USA for the reversal of rivaroxaban- and apixaban-related bleeding only, 
following positive results from clinical trials.23,24 Another potential FXa inhibitor reversal 
agent, ciraparantag, has yet to begin phase II or III evaluation in patient settings; phase II 
































































data in healthy volunteers administered rivaroxaban (NCT03172910) or apixaban 
(NCT03288454) are expected in 2019. 
The RE-VECTO surveillance programme was designed to collect data on drug use in a 
simple and effective way, although the voluntary registration design and/or resource 
limitations may have reduced participation and resulted in some approximately 10% of 
patients having incomplete datasets., and Some recruited sites known to be prescribing 
idarucizumab that did not enter patient data in the registry during the specified time period 
of time of  for data collection, and were not actively surveyed. Data listing reviews 
conducted prior to database lock did not involve an independent data review committee, 
and on-site source data verification was not conducted. Administration of idarucizumab is 
rare, and without patient data being entered into the registry, we are unable to ascertain 
whether these sites wereare re-stocking idarucizumab, supplying satellite locations within 
the hospital, replacing expired idarucizumab, or administering idarucizumab to patients. In 
addition, this surveillance programme had no pre-specified data management plan or 
independent review as part of the protocol, and some patient information was missing. 
Nevertheless, dDrug surveillance programmes are one source of real-world data,25 that are 
particularly useful for identifying improper use. By identifying potential risks, action can be 
taken to help minimise the risk of adverse drug reactions resulting from medication errors. 
This study assessed idarucizumab utilization in a pre-defined sample of prescriptions in the 
clinical practice setting, based on medical and pharmacy record review. This approach was 
in line with post-marketing surveillance requested by the European Medicines Agency. 
Conclusion
































































Real-world information from the RE-VECTO surveillance programme adds to the data 
obtained from idarucizumab clinical trials and provides valuable insights into the current 
strategies employed to reverse the anticoagulation effects of dabigatran in emergency 
situations. Usage patterns of idarucizumab were closely aligned with data from the clinical 
trial settingidarucizumab prescribing information, with minimal off-label use. 
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Fig. 1 Location of bleedinga events (N = 207) leading to idarucizumab use, and idarucizumab 
use by bleeding location. 
aLife-threatening or uncontrolled bleeding requiring medical intervention.
b Calculated only for those patients administered total dose of 5 g (2 vials), and defined as 
the end time of second vial minus the start time of the first vial. If the start or end time of 
dosing was unknown, the estimated time of total infusion was used; if this estimate was not 
known, then time was set to missing.
c Missing data for 28 patients with gastrointestinal tract bleeding, 25 with intracranial 
bleeding, 3 with skin bleeding, 3 with urogenital tract bleeding, 1 with intramuscular 
bleeding, 2 with retroperitoneal bleeding, and 6 with other bleeding locations.
































































Abbreviations: GI, gastrointestinal; NE, not evaluable; SD, standard deviation.
































































Fig. 2 Type of surgery or procedure by indication for idarucizumab use. 
a Missing data for 8 patients undergoing emergency surgery or other urgent medical 
procedures.
b Missing data for 1 patient undergoing scheduled or planned surgery/procedures.

































































Table 1 Hospitals treating patients with idarucizumab by regionParticipating hospitals by region



















































































































































































Availability of electronic prescription records at 

































Total number of idarucizumab units (2 × 2.5 g) 
stocked per hospital pharmacy in all storage 
locationsc, n (%)
8 24 28 60
































































Median (IQR) 2.0 (1.0, 3.0) 2.0 (2.0, 3.5) 2.0 (1.0, 2.0) 2.0 (1.0, 3.0)





















a Type 1: academic sector type; Type 2: practice hospital type.
b Only available when type of pharmacy is decentralised pharmacy.
c Data for 1 hospital pharmacy missing for North America.
d Multiple answers possible. 
Abbreviations: IQR, interquartile range.
































































Table 2 Characteristics of patients treated with idarucizumab by region



















































































































































































Other 0 ( 0.0) 0 (0.0) 5 ( 3.2) 5 (1.4)
















a Type 1: academic sector type; Type 2: practice hospital type.
































































Table 3 Last anticoagulant medication taken prior to recruitment, according to the reason for idarucizumab administration





















































































































































a Includes two patients who received ≥ 1 dose dabigatran plus other anticoagulant.
b Includes two patients who were receiving another known anticoagulant medication.











































































































Table 4 Idarucizumab utilisation according to the reason for idarucizumab administration





















































































Idarucizumab total dose, n (%)
2.5 g (1 vial)































































































































































































a Life-threatening or uncontrolled bleeding requiring urgent medical intervention.
b Emergency surgery or other urgent medical procedure necessitating rapid reversal of dabigatran prior to surgery or procedure (emergency 
defined as within the next 8 hours).
c Calculated only for those patients administered total dose of 5 g (2 vials), and defined as the end time of second vial minus the start time of 
the first vial. If the start or end time of dosing was unknown, the estimated time of total infusion was used; if this estimate was not known, 
then time was set to missing.
d Missing data for 68 patients in the Emergency setting, 40 in the Operating setting, 5 in the intensive care setting, and 10 in the Other setting.
e Among patients who had second round of dosing with 5 g of idarucizumab.
f Missing data for 1 patient in the Emergency and ICU settings.
Abbreviations: SD, standard deviation.












































































Fig. 1 Location of bleedinga events (N = 207) leading to idarucizumab use, and idarucizumab use by 
bleeding location. 
aLife-threatening or uncontrolled bleeding requiring medical intervention. 
b Calculated only for those patients administered total dose of 5 g (2 vials), and defined as the end time of 
second vial minus the start time of the first vial. If the start or end time of dosing was unknown, the 
estimated time of total infusion was used; if this estimate was not known, then time was set to missing. 
c Missing data for 28 patients with gastrointestinal tract bleeding, 25 with intracranial bleeding, 3 with skin 
bleeding, 3 with urogenital tract bleeding, 1 with intramuscular bleeding, 2 with retroperitoneal bleeding, 
and 6 with other bleeding locations. 
Abbreviations: GI, gastrointestinal; NE, not evaluable; SD, standard deviation. 
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Fig. 2 Type of surgery or procedure by indication for idarucizumab use. 
a Missing data for 8 patients undergoing emergency surgery or other urgent medical procedures.
b Missing data for 1 patient undergoing scheduled or planned surgery/procedures. 
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